The present invention contemplates compositions comprising compounds, in particular dihydroeugenol (DHE) and/or isoeugenol (IE) and/or ethyl vanillin (EV) or salts, esters, ethers, or derivatives thereof, and methods for topically or systemically delivering them for treatment against inflammation-related and other dermatological conditions such as described herein. These DHE and/or IE and/or EV or salts, esters, ethers or derivatives thereof also are delivered to a measurable extent transepidermally or transdermally and thus may have systemic and/or localized anti¬ inflammatory effects within the body. In one of its method aspects, this invention is directed to a method for treating a patient with a dermatological disease or condition by topically administering to said patient a pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically acceptable topical carrier and an effective dermatological disease, disorder or condition-treating amount of a formulation of DHE and/or IE and/or EV, or salts, esters, ethers, or derivatives thereof. In particular, the present invention is directed to a method of using a composition comprising one or more of DHE and/or IE and/or EV or salts, esters, ethers, or derivatives for treating dermatologic diseases, disorders or conditions, aging effects related to decreasing production of collagen, elastin, or hyaluronic acid, or to hyperpigmentation. The formulations may further contain cinnamaldehyde.Cette invention concerne des compositions comprenant des composés, en particulier du dihydro-eugénol (DHE) et/ou de lisoeugénol (IE) et/ou de léthylvanilline (EV) ou leurs sels, leurs esters, leurs éthers ou leurs dérivés, et des procédés pour les administrer par voie topique ou systémique en vue de traiter des affections associées avec linflammation et des affections dermatologiques comme décrit ici. Le DHE et/ou lIE et/ou lEV ou leurs sels, leurs esters, leurs éthers ou leurs dérivés sont aussi administrés à un deg